企业紧紧围绕国家重大疾病治疗药物和新型代谢综合征防治药物研究方向，积极进行原创药物的研发及产业化研究，先后承担国家新产品计划、国家科技型中小企业技术创新项目、省、市科技项目10余项。
14 Independent scientific research project
Total number of 14
core patents
2 provincial R & D
institutions
R&D Overview
科技扶持
Hencer steadfastly upholds the spirit of development, which is “always give prior consideration to technology, put quality of products at a paramount place, lead the industry standard and manage scientifically,” meanwhile being named Research Center of Polysaccharide Iron Compound Medicine in Jiangsu Province and Technology Center of Enterprise Identified by Jiangsu Province. Additionally, Nanjing Lifenergy R&D Co. Ltd, as a wholly owned subsidiary of Nanjing Hencer Pharmaceutical Co. Ltd, annually invests a plenty of money on research and development, which accounts for 8%-10% of sales revenue.
Modern laboratories that conforms to GLP standard are built in R&D center, where is equipped with cutting-edge scientific apparatuses and analytical devices with international caliber. So our R&D center can shoulder a series of medical work, including assessment of project, drug screening, establishments of quality standard of APIs and formulations, clinic research, the process of drug registration and approval, etc.
Hencer orientates its products in nephrology area. There are more than fourteen research projects at present, and six of which are centering on the field of nephrology and three projects have link with the field of cardiovascular and thrombin inhibitors.
Hencer is guided by the concept of "valuable research", sticking to the principle "innovation derived from generics other than purely imitation", targeting at "the best quality in globe" and establishing" patent barriers" and "standard barriers", to constantly enhance the value of products and technology.
R&D Results
恒生制药在产品研制中坚持“仿中有创”和研发水平的持续升级，以高度创新的仿制产品挑战原研产品；经过多年的努力，公司已从原来“产品质量标准的跟随者”发展成为“产品质量标准的改进者”。
国家标准
恒生制药拥有生产批件41个，涉及化学原料药、注射剂、滴眼剂、口服液及口服固体等剂型，产品以化药为主，中成药为辅。
生产批件
截至目前，企业拥有有效专利及专利申请共46件，其中有效发明专利13件，美国PCT专利1件；申请发明专利15件。
专利申请
Hencer is people-oriented, and the R&D center has a first-class team with professional pharmaceutical background, who are capable with bringing products into industrialization. There are 86 personnel in R&D center, including 2 doctors, 8 senior engineers and 16 intermediate engineers.
At the same time, Hencer employs well-known experts at home and abroad, in order to create technology upgrading in key areas. Hencer's competitive advantages lie in effective combination of talents and resource distributions.
R&D Team
